INCB086550
INCB086550 is a potent, oral, small-molecule PD-L1 inhibitor with IC50s value of 3.1, 4.9 and 1.9 nM for human, cynomolgus, and rat, respectively. INCB086550 promotes the dimerization of cell-surface PD-L1 and induces PD-L1 entry into Golgi vesicles then traffick to the nucleus. INCB086550 can be used for multiple cancers research[1].
Product Specifications
CAS Number
2230911-59-6
Product Name Alternative
PD-1/PD-L1-IN-8
UNSPSC
12352005
Hazard Statement
H302, H315, H319
Target
PD-1/PD-L1
Type
Reference compound
Related Pathways
Immunology/Inflammation
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/incb086550.html
Purity
99.80
Solubility
DMSO : 100 mg/mL (ultrasonic) |H2O : 83.33 mg/mL (ultrasonic; adjust pH to 3 with HCl)
Smiles
N#CC1=C2C(N=C(C3=C(C(C4=C(C(NC5=NC=CC6=C5N=CC(CN7CC[C@H](C7)O)=C6)=CC=C4)C)=CC=C3)C)O2)=CC(CN8C[C@@H](CC8)C(O)=O)=C1
Molecular Formula
C41H39N7O4
Molecular Weight
693.79
Precautions
H302, H315, H319
References & Citations
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Phase 2
Available Sizes
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
![[[3,3',3''-(Phosphinidyne-KappaP)tris[benzenesulfonato]](3-)]-Palladate(3-) Sodium](https://cdn.genprice.uk/products/572/4720874345881/imageurl/trc-p353835-1mg.webp)
[[3,3',3''-(Phosphinidyne-KappaP)tris[benzenesulfonato]](3-)]-Palladate(3-) Sodium
CD8A (Cytotoxic-&Suppressor T-Cell Marker) (rC8/468), CF640R conjugate, 0.1mg/mL
